Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and United Therapeutics (UTHR) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlig ...

Core Insights - United Therapeutics is a biotechnology company focused on developing treatments for chronic and life-threatening conditions, particularly pulmonary arterial hypertension (PAH) and pediatric neuroblastoma [1] Financial Performance - The company reported a 12% increase in earnings per share for Q3 2025, reaching $7.16, surpassing the Zacks Consensus Estimate of $6.89 [3][6] - Revenues for the quarter were $799.5 million, which was below the expected $818 million but still represented a 7% year-over-year growth [3] Product Sales - Tyvaso sales grew by 10%, while Tyvaso DPI saw a significant increase of 22% [4][6] - The TETON-2 study indicated that Tyvaso improved lung function in patients with idiopathic pulmonary fibrosis (IPF), suggesting potential for future growth [4] Stock Performance - UTHR's stock is currently trading at $455.32, reflecting a notable increase of 9.63% or $39.98 [5][6] - The stock has fluctuated between $415.26 and $479.50 on the trading day, with a market capitalization of approximately $20.59 billion [5]

Key Takeaways United Therapeutics' Q3 EPS rose 12% to $7.16, which topped expectations but revenues missed.Overall Tyvaso sales climbed 10% year over year, led by 22% growth in Tyvaso DPI.TETON-2 study showed Tyvaso improved lung function in IPF patients, supporting future growth.United Therapeutics (UTHR) reported third-quarter 2025 earnings of $7.16 per share, which beat the Zacks Consensus Estimate of $6.89. Earnings rose 12% year over year on the back of higher product sales.United Therapeutics markets ...

Core Insights - United Therapeutics (UTHR.US) shares surged over 12%, reaching a record high of $465.38 [1] - The company reported Q3 2025 earnings of $7.16 per share, exceeding analyst expectations by approximately $0.16 [1] - Net profit reached $338.7 million, reflecting a year-over-year growth of about 9.6% [1] - The main product, Tyvaso, showed continued double-digit growth, contributing to a record total revenue of $799.5 million, a year-over-year increase of 7% [1]

Core Insights - United Therapeutics reported revenue of $799.5 million for the quarter ended September 2025, reflecting a year-over-year increase of 6.8% [1] - The company's EPS was $7.16, up from $6.39 in the same quarter last year, indicating a positive earnings performance [1] - Revenue fell short of the Zacks Consensus Estimate of $817.8 million, resulting in a surprise of -2.24%, while EPS exceeded expectations by 3.92% [1] Revenue Breakdown - U.S. revenues were $774.8 million, compared to an estimated $810.22 million, marking an 8% increase year-over-year [4] - Revenues from the Rest-of-World segment were $24.7 million, below the estimated $33.09 million, representing a decline of 21.8% year-over-year [4] - Tyvaso generated $470.1 million in U.S. revenue, falling short of the $507.8 million estimate, while Unituxin brought in $46.5 million, below the $62.24 million estimate [4] - Adcirca revenues were $9.7 million, exceeding the $5.49 million estimate, with a significant year-over-year increase of 38.6% [4] - Orenitram revenues reached $131.1 million, slightly above the $124.02 million estimate, reflecting a 15.8% year-over-year increase [4] - Tyvaso DPI revenues were $336.2 million, surpassing the $322.54 million estimate, with a year-over-year growth of 22.4% [4] - Other products generated $6.9 million, exceeding the $5.35 million estimate, with a year-over-year increase of 25.5% [4] Stock Performance - Over the past month, United Therapeutics shares have returned -0.9%, contrasting with the Zacks S&P 500 composite's increase of 3.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

United Therapeutics (NasdaqGS:UTHR) Q3 2025 Earnings Call October 29, 2025 09:00 AM ET Company ParticipantsMichael Benkowitz - President and COOHarrison Silvers - Investor Relations ManagerPat Poisson - EVP of Strategic DevelopmentLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Founder, Chairman, and CEOConference Call ParticipantsOlivia Breyer - Senior Equity AnalystJoseph Thome - Managing Director and Senior Research AnalystAndreas Argyrides - Managing Director and S ...

United Therapeutics (NasdaqGS:UTHR) Q3 2025 Earnings Call October 29, 2025 09:00 AM ET Company ParticipantsMichael Benkowitz - President and COOHarrison Silvers - Investor Relations ManagerPat Poisson - EVP of Strategic DevelopmentLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Founder, Chairman, and CEOConference Call ParticipantsOlivia Breyer - Senior Equity AnalystJoseph Thome - Managing Director and Senior Research AnalystAndreas Argyrides - Managing Director and S ...

United Therapeutics (NasdaqGS:UTHR) Q3 2025 Earnings Call October 29, 2025 09:00 AM ET Speaker2Good morning everyone and welcome to the United Therapeutics Corporation Third Quarter 2025 Corporate Update. My name is Jamie and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen-only mode until the question and answer portion of this earnings call. If you'd like to ask a question during that time, please press STAR and the number one on your telep ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Safe Harbor Statement United Therapeutics Corporation Third Quarter 2025 Corporate Update October 29, 2025 2 INTRODUCTION We caution you that these statements are not guarantees of future performance and are subject to numerous evolving risks and uncertainties that we may not be able to accurately predict or assess, including the risk factors that we describe in our Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q. Any of these ...